Since dual BRAF and ERK1/2 inhibition effectively abrogates clonal outgrowth of BRAFV600E colorectal cancer cells, which have relatively high intrinsic resistance to BRAFi/MEKi combination [49], the addition of ERK inhibition to the combination strategy is promising. Here, BRAF is linked to colorectal cancer.